Enhancement of oral bioavailability of cilostazol by forming its inclusion complexes

AAPS PharmSciTech

Volumn 10, Issue 2, 2009, Pages 660-669

  Patel, Samir G ^a   Rajput, Sadhana J ^b  

^a CHAROTAR UNIVERSITY OF SCIENCE AND TECHNOLOGY   (India)

^b M S UNIVERSITY OF BARODA   (India)

Author keywords

Bioavailability; Cilostazol CD inclusion complex; Dissolution; Solubility; Stability study

Indexed keywords

BETA CYCLODEXTRIN; BUFFER; CILOSTAZOL; GAMMA CYCLODEXTRIN; PLETOZ 50; UNCLASSIFIED DRUG; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; CYCLODEXTRIN; HEPTAKIS(2,6 O DIMETHYL)BETA CYCLODEXTRIN; HEPTAKIS(2,6-O-DIMETHYL)BETA-CYCLODEXTRIN; TETRAZOLE DERIVATIVE;

ACIDITY; ANIMAL EXPERIMENT; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; NONHUMAN; PRECIPITATION; RABBIT; SALINITY; STOICHIOMETRY; THERMOSTABILITY; X RAY DIFFRACTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; ORAL DRUG ADMINISTRATION; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CYCLODEXTRINS; DRUG STABILITY; RABBITS; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TETRAZOLES; X-RAY DIFFRACTION;

EID: 67549093409     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-009-9249-7     Document Type: Article

References (29)

1. Medical EconomicsPhysicians. Physicians' desk reference. 59th ed. Stamford: Thomson; 2005. p. 2564-6.
2. Larsen KL. Large cyclodextrins. J Inclusion Phenom Macro Chem. 2002;43(1-2):1-13.
3. Szejtli J, Osa T. Comprehensive supramolecular chemistry: Cyclodextrins, vol 3. Oxford: Pergamon; 1996.
4. Uekama K, Hirayama F, Irie T. Cyclodextrin drug carrier systems. Chem Rev. 1998;98(5):2045-76.
5. Mosher G, Thompson D. Complexation and cyclodextrins. encyclopedia of pharmaceutical technology, Vol. 19. New York: Marcel and Dekker; 1999. p. 49-88.
6. Homans SW. A molecular mechanical force field for the conformational analysis of oligosaccharides: Comparison of the theoretical and crystal structure of Manα1-3Manβ1-4GlcNAc. Biochemistry 1990;29(39):9110-8.
7. Zuo Z, Kwon G, Stevenson B, Diakur J, Wiebe LI. Flutamide-hydroxypropyl-β-cyclodextrin complex: Formulation, physical characterization, and absorption studies using the Caco-2 in vitro model. J Pharm Pharmceut Sci. 2000;3(2):220-7.
8. Dollo G, Corre PL, Chollet M, Chevanne F, Bertault M, Burgot JL, et al. Improvement in solubility and dissolution rate of 1,2-dithiole-3-thiones upon complexation with β-cyclodextrin and its hydroxypropyl and sulfobutyl ether-7 derivatives. J Pharm Sci. 1999;88:889-95.
9. Duchene D. New trends in cyclodextrins and derivatives. Paris: Editios de Sante; 1992. p. 351-407.
10. Fromming KH, Szejtli J. Cyclodextrins in pharmacy (Topics in inclusion science). Dordrecht: Kulwer Academic; 1994.
11. Thompson DO. Cyclodextrin-enabling excipients: Their present and future use in pharmaceuticals. Crit Rev Ther Drug Carrier Syst. 1997;14:1-104.
12. Masson M, Loftsson T, Masson G, Stefansson E. Cyclodextrin as permeation enhancer: Some theoretical evaluations and in vitro testing. J Control Release 1999;59(1):107-18.
13. Govt. of India, Ministry of Health and Family Welfare. Pharmacopoeia of India, vol I. 4th ed. New Delhi: Controller of Publication; 1996. p. A-144-7.
14. Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Inst. 1965;4:117-212.
15. Attama AA, Ndibe ON, Nnamani PO. Studies on diclofenac β-cyclodextrin inclusion complexes. J Pharm Res. 2004;3:47-9.
16. Liu X, Lin HS, Thenmozhiyal JC, Chan SY, Ho PC. Inclusion of acitretin cyclodextrins: Phase solubility, photostability, and physicochemical characterization. J Pharm Sci. 2003;92(12):2449-57.
17. Hidetoshi A, Kiyokazu Y, Kouzou M, Tetsumi I, Fumitoshi H, Kaneto U. Comparative studies of the enhancing effect of cyclodextrins on the solubility and oral bioavailability of tacrolimus rats. J Pharm Sci. 2001;90(6):690-701.
18. Rawat S, Jain SK. Roficoxib-beta cyclodextrin inclusion complex for solubility enhancement. Pharmazie. 2003;58(9):639-41.
19. Manca ML, Zaru M, Ennas G, Valenti D, Sinico C, Loy G, Fadda AM. Diclofenac-β-cyclodextrin binary systems: Physical characterization and in vitro dissolution and diffusion studies. AAPS Pharm Sci Tech. 2005;6(3):E464-72.
20. Castro-Hermida JA, Gomez-Couso H, Ares-Mazas ME, Gonzalez-Bedia MM, Castaneda-Cancio N, Otero-Espinar FJ, et al. Anticryptosporidal activity of furan derivative G1 and its inclusion complex with beta-cyclodextrin. J Pharm Sci. 2004;93(1):197-206.
21. Nalluri BN, Chowdary KPR, Murthy KVR, Satyanarayana V, Hayman AR, Becket G. Inclusion complexation and dissolution properties of nimesulide and meloxicam-hydroxypropyl-β-cyclodextrin binary systems. J Inclusion Sci Macro Chem. 2005;53(1-2):103-10.
22. United State Pharmacopoeia. Dissolution study, XXIII, NF XVIII. Rockville: USP Convention; 1995. p. 1791-9.
23. Khan KA, Rhodes CT. Concept of dissolution efficiency. J Pharm Pharmacol. 1975;27(1):48-9.
24. Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20(6):64-74.
25. 2). Pharm Res. 1998;15(6):889-96.
26. Gibaldi M, Perrier D. Pharmacokinetics (Drugs and the pharmaceutical sciences), 2nd edn, vol. 15. New York: Marcel Dekker, 1982, revised and expanded.
27. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: An updated review. AAPS Pharm Sci Tech. 2005;06(02):E329-57.
28. Wan-Liang L, Qiang Z, Li Z, Hua W, Rong-Yu L, Li-Feng Z, et al. Antipyretic, analgesic and anti-inflammatory activities of ketoprofen β-cyclodextrin inclusion complexes in animals. Bio Pharm Bull. 2004;27(10):1515-20.
29. Ali H, Marzouqi A, Shehatta I, Jobe B, Dowaidar A. Phase solubility and inclusion complex of itraconazole with β-cyclodextrin using supercritical carbon dioxide. J Pharm Sci. 2006;95(2):292-304.